| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Catheter Ablation | 85 | 2023 | 2746 | 9.990 |
Why?
|
| Tachycardia, Ventricular | 49 | 2023 | 1272 | 7.120 |
Why?
|
| Sarcoidosis | 22 | 2023 | 503 | 4.260 |
Why?
|
| Defibrillators, Implantable | 37 | 2023 | 1440 | 3.860 |
Why?
|
| Cardiomyopathies | 29 | 2023 | 1912 | 3.520 |
Why?
|
| Arrhythmias, Cardiac | 26 | 2023 | 2267 | 3.320 |
Why?
|
| Atrial Fibrillation | 44 | 2023 | 5019 | 2.820 |
Why?
|
| Pulmonary Veins | 13 | 2019 | 759 | 2.520 |
Why?
|
| Electrocardiography | 45 | 2024 | 6440 | 2.410 |
Why?
|
| Heart Conduction System | 16 | 2023 | 1048 | 2.210 |
Why?
|
| Therapeutic Irrigation | 9 | 2023 | 300 | 2.150 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 23 | 2019 | 489 | 2.000 |
Why?
|
| Myocardium | 15 | 2023 | 4775 | 1.710 |
Why?
|
| Ventricular Fibrillation | 12 | 2022 | 538 | 1.610 |
Why?
|
| Electrodes | 4 | 2018 | 615 | 1.600 |
Why?
|
| Endocardium | 5 | 2023 | 261 | 1.480 |
Why?
|
| Atrioventricular Block | 5 | 2019 | 120 | 1.430 |
Why?
|
| Pacemaker, Artificial | 10 | 2024 | 817 | 1.410 |
Why?
|
| Pericardium | 8 | 2023 | 667 | 1.390 |
Why?
|
| Heart Injuries | 2 | 2023 | 209 | 1.270 |
Why?
|
| Cattle | 16 | 2023 | 3923 | 1.230 |
Why?
|
| Ventricular Premature Complexes | 6 | 2022 | 111 | 1.190 |
Why?
|
| Electric Countershock | 15 | 2022 | 535 | 1.180 |
Why?
|
| Heart Block | 5 | 2018 | 410 | 1.170 |
Why?
|
| Coronary Sinus | 2 | 2020 | 87 | 1.160 |
Why?
|
| Sarcoidosis, Pulmonary | 3 | 2017 | 43 | 1.100 |
Why?
|
| Tachycardia, Supraventricular | 6 | 2022 | 263 | 1.090 |
Why?
|
| Heart Ventricles | 14 | 2023 | 3801 | 1.080 |
Why?
|
| Heart Rate | 14 | 2021 | 4091 | 1.080 |
Why?
|
| Atrial Appendage | 3 | 2023 | 282 | 1.080 |
Why?
|
| Cardiac Surgical Procedures | 5 | 2023 | 3526 | 0.990 |
Why?
|
| Heart Septum | 4 | 2016 | 313 | 0.970 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 3 | 2021 | 137 | 0.960 |
Why?
|
| Propanolamines | 7 | 2021 | 167 | 0.940 |
Why?
|
| Atrial Flutter | 6 | 2021 | 264 | 0.930 |
Why?
|
| Cardiac Pacing, Artificial | 8 | 2011 | 846 | 0.920 |
Why?
|
| Accessory Atrioventricular Bundle | 3 | 2021 | 56 | 0.880 |
Why?
|
| Heart Atria | 6 | 2023 | 1348 | 0.870 |
Why?
|
| Action Potentials | 7 | 2019 | 1814 | 0.860 |
Why?
|
| Bundle of His | 4 | 2021 | 88 | 0.850 |
Why?
|
| Anti-Arrhythmia Agents | 13 | 2022 | 790 | 0.850 |
Why?
|
| Equipment Failure | 6 | 2012 | 579 | 0.820 |
Why?
|
| Temperature | 5 | 2023 | 2207 | 0.820 |
Why?
|
| Hot Temperature | 4 | 2023 | 1355 | 0.820 |
Why?
|
| Body Surface Potential Mapping | 8 | 2019 | 238 | 0.810 |
Why?
|
| Liposomes | 2 | 2023 | 758 | 0.810 |
Why?
|
| Cardiac Resynchronization Therapy | 4 | 2024 | 532 | 0.790 |
Why?
|
| Ventricular Function, Left | 14 | 2023 | 3656 | 0.780 |
Why?
|
| Electrodes, Implanted | 3 | 2023 | 824 | 0.760 |
Why?
|
| Cicatrix | 4 | 2023 | 761 | 0.760 |
Why?
|
| Amiodarone | 3 | 2017 | 212 | 0.720 |
Why?
|
| Tachycardia, Reciprocating | 2 | 2017 | 15 | 0.700 |
Why?
|
| Bundle-Branch Block | 3 | 2020 | 270 | 0.670 |
Why?
|
| Ventricular Dysfunction, Left | 8 | 2018 | 2059 | 0.670 |
Why?
|
| Tachycardia | 4 | 2022 | 620 | 0.660 |
Why?
|
| Esophageal Fistula | 1 | 2019 | 64 | 0.660 |
Why?
|
| Receptors, Adrenergic, beta-1 | 6 | 2021 | 51 | 0.660 |
Why?
|
| Papillary Muscles | 4 | 2022 | 200 | 0.620 |
Why?
|
| Heart | 6 | 2023 | 4462 | 0.600 |
Why?
|
| Catheters | 5 | 2023 | 422 | 0.600 |
Why?
|
| Electric Impedance | 4 | 2022 | 727 | 0.570 |
Why?
|
| Arrhythmogenic Right Ventricular Dysplasia | 3 | 2014 | 161 | 0.570 |
Why?
|
| Humans | 188 | 2024 | 742088 | 0.560 |
Why?
|
| Equipment Failure Analysis | 3 | 2010 | 867 | 0.560 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 2016 | 31 | 0.550 |
Why?
|
| Heart Failure | 15 | 2024 | 10856 | 0.550 |
Why?
|
| Electrocardiography, Ambulatory | 4 | 2019 | 585 | 0.540 |
Why?
|
| Myocarditis | 4 | 2023 | 770 | 0.540 |
Why?
|
| Heart Diseases | 6 | 2023 | 2789 | 0.520 |
Why?
|
| Ventricular Function, Right | 1 | 2019 | 592 | 0.520 |
Why?
|
| Equipment Design | 10 | 2023 | 3582 | 0.520 |
Why?
|
| Ablation Techniques | 2 | 2016 | 249 | 0.520 |
Why?
|
| Thermography | 1 | 2015 | 67 | 0.510 |
Why?
|
| Materials Testing | 2 | 2016 | 865 | 0.510 |
Why?
|
| Pericardial Effusion | 1 | 2017 | 246 | 0.510 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 2016 | 117 | 0.510 |
Why?
|
| Device Removal | 3 | 2020 | 652 | 0.500 |
Why?
|
| Treatment Outcome | 57 | 2024 | 62966 | 0.500 |
Why?
|
| Ferric Compounds | 1 | 2016 | 374 | 0.480 |
Why?
|
| Middle Aged | 92 | 2023 | 213127 | 0.480 |
Why?
|
| Ethanol | 3 | 2016 | 1337 | 0.480 |
Why?
|
| Esophagus | 2 | 2023 | 1017 | 0.480 |
Why?
|
| Nanotubes, Carbon | 1 | 2014 | 73 | 0.470 |
Why?
|
| Prosthesis Implantation | 3 | 2015 | 641 | 0.470 |
Why?
|
| Stroke Volume | 18 | 2023 | 4983 | 0.470 |
Why?
|
| Energy Transfer | 1 | 2013 | 109 | 0.470 |
Why?
|
| Diagnostic Errors | 3 | 2011 | 1255 | 0.460 |
Why?
|
| Pulmonary Fibrosis | 1 | 2017 | 526 | 0.450 |
Why?
|
| Sodium Chloride | 2 | 2015 | 625 | 0.450 |
Why?
|
| Swine | 8 | 2023 | 5934 | 0.450 |
Why?
|
| Male | 113 | 2022 | 349538 | 0.440 |
Why?
|
| Septal Occluder Device | 1 | 2014 | 129 | 0.440 |
Why?
|
| Heart Transplantation | 5 | 2023 | 3119 | 0.440 |
Why?
|
| Hepatic Veins | 1 | 2013 | 112 | 0.440 |
Why?
|
| Death, Sudden, Cardiac | 10 | 2022 | 1541 | 0.440 |
Why?
|
| Adrenergic beta-Antagonists | 7 | 2021 | 1239 | 0.430 |
Why?
|
| Echocardiography | 8 | 2020 | 5097 | 0.430 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2013 | 194 | 0.420 |
Why?
|
| Environment | 1 | 2018 | 1115 | 0.420 |
Why?
|
| Aged | 76 | 2021 | 162944 | 0.420 |
Why?
|
| Cryosurgery | 3 | 2023 | 453 | 0.420 |
Why?
|
| Postoperative Complications | 10 | 2020 | 15244 | 0.420 |
Why?
|
| Recurrence | 15 | 2022 | 8333 | 0.420 |
Why?
|
| Radiosurgery | 1 | 2021 | 1309 | 0.410 |
Why?
|
| Atrioventricular Node | 3 | 2021 | 182 | 0.410 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2016 | 1263 | 0.410 |
Why?
|
| Metal Nanoparticles | 1 | 2016 | 403 | 0.400 |
Why?
|
| Electrophysiological Phenomena | 1 | 2013 | 316 | 0.400 |
Why?
|
| Heart-Assist Devices | 5 | 2017 | 1194 | 0.400 |
Why?
|
| Female | 105 | 2022 | 379592 | 0.390 |
Why?
|
| Tetralogy of Fallot | 4 | 2018 | 623 | 0.390 |
Why?
|
| Epicardial Mapping | 2 | 2021 | 57 | 0.370 |
Why?
|
| Myocardial Infarction | 9 | 2011 | 11690 | 0.320 |
Why?
|
| Time Factors | 26 | 2023 | 40054 | 0.320 |
Why?
|
| Colorado | 5 | 2019 | 162 | 0.310 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 1237 | 0.310 |
Why?
|
| Adult | 56 | 2022 | 213712 | 0.300 |
Why?
|
| Hypertension, Pulmonary | 1 | 2017 | 1527 | 0.290 |
Why?
|
| Perciformes | 2 | 2018 | 18 | 0.280 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2012 | 851 | 0.280 |
Why?
|
| Prosthesis-Related Infections | 2 | 2023 | 538 | 0.270 |
Why?
|
| Risk Assessment | 17 | 2020 | 23320 | 0.260 |
Why?
|
| Predictive Value of Tests | 14 | 2019 | 15056 | 0.260 |
Why?
|
| Pulmonary Valve | 3 | 2018 | 437 | 0.250 |
Why?
|
| Retrospective Studies | 36 | 2022 | 77098 | 0.250 |
Why?
|
| Animals | 23 | 2023 | 168561 | 0.250 |
Why?
|
| Cardiotonic Agents | 1 | 2007 | 535 | 0.240 |
Why?
|
| Heart Arrest | 2 | 2011 | 1469 | 0.240 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2006 | 277 | 0.240 |
Why?
|
| Philadelphia | 5 | 2019 | 263 | 0.240 |
Why?
|
| Risk Factors | 30 | 2023 | 72145 | 0.240 |
Why?
|
| Electric Stimulation Therapy | 1 | 2010 | 605 | 0.240 |
Why?
|
| Atrial Premature Complexes | 2 | 2017 | 17 | 0.240 |
Why?
|
| Glucose | 1 | 2015 | 4391 | 0.220 |
Why?
|
| Multivariate Analysis | 14 | 2022 | 12242 | 0.220 |
Why?
|
| Nanoparticles | 1 | 2014 | 1902 | 0.220 |
Why?
|
| Cardiology | 4 | 2020 | 1658 | 0.220 |
Why?
|
| Tachycardia, Ectopic Atrial | 1 | 2022 | 66 | 0.210 |
Why?
|
| Registries | 7 | 2021 | 8077 | 0.210 |
Why?
|
| Aortic Valve | 4 | 2020 | 1911 | 0.210 |
Why?
|
| Prosthesis Failure | 2 | 2020 | 1203 | 0.210 |
Why?
|
| Prospective Studies | 21 | 2023 | 53187 | 0.200 |
Why?
|
| Apnea | 1 | 2023 | 195 | 0.200 |
Why?
|
| Reoperation | 5 | 2019 | 4200 | 0.200 |
Why?
|
| Stroke | 2 | 2023 | 9963 | 0.200 |
Why?
|
| Body Temperature | 2 | 2015 | 776 | 0.200 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2021 | 18 | 0.200 |
Why?
|
| Pre-Excitation Syndromes | 1 | 2021 | 27 | 0.200 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2006 | 719 | 0.200 |
Why?
|
| Metoprolol | 2 | 2019 | 93 | 0.190 |
Why?
|
| Cardiography, Impedance | 1 | 2020 | 41 | 0.190 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2004 | 1517 | 0.190 |
Why?
|
| Follow-Up Studies | 19 | 2021 | 39004 | 0.190 |
Why?
|
| Odds Ratio | 10 | 2017 | 9846 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 8 | 2018 | 6534 | 0.170 |
Why?
|
| Secondary Prevention | 3 | 2017 | 1520 | 0.170 |
Why?
|
| Systole | 2 | 2019 | 956 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2023 | 20086 | 0.170 |
Why?
|
| Pennsylvania | 4 | 2009 | 613 | 0.170 |
Why?
|
| Electrophysiology | 2 | 2015 | 1309 | 0.170 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 4147 | 0.170 |
Why?
|
| Aortic Valve Stenosis | 3 | 2020 | 1941 | 0.160 |
Why?
|
| Incidence | 11 | 2021 | 20928 | 0.160 |
Why?
|
| Electroencephalography | 3 | 2011 | 6142 | 0.160 |
Why?
|
| Heart Septal Defects, Ventricular | 2 | 2019 | 485 | 0.160 |
Why?
|
| Hydroxychloroquine | 1 | 2022 | 408 | 0.160 |
Why?
|
| Abnormalities, Multiple | 2 | 2019 | 1416 | 0.160 |
Why?
|
| Cohort Studies | 12 | 2018 | 40450 | 0.160 |
Why?
|
| Graft Rejection | 1 | 2011 | 4393 | 0.160 |
Why?
|
| Disease Management | 3 | 2020 | 2450 | 0.150 |
Why?
|
| Long QT Syndrome | 2 | 2013 | 453 | 0.150 |
Why?
|
| Primary Prevention | 2 | 2017 | 1166 | 0.150 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 1028 | 0.150 |
Why?
|
| Sus scrofa | 1 | 2018 | 437 | 0.150 |
Why?
|
| Survival Rate | 6 | 2019 | 12773 | 0.150 |
Why?
|
| Thermal Conductivity | 1 | 2016 | 16 | 0.140 |
Why?
|
| Doxorubicin | 1 | 2023 | 2215 | 0.140 |
Why?
|
| Nocturnal Myoclonus Syndrome | 1 | 2016 | 50 | 0.140 |
Why?
|
| Biophysical Phenomena | 1 | 2017 | 327 | 0.140 |
Why?
|
| Prosthesis Fitting | 1 | 2016 | 74 | 0.140 |
Why?
|
| Cheyne-Stokes Respiration | 1 | 2016 | 38 | 0.140 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 314 | 0.140 |
Why?
|
| Heart Defects, Congenital | 3 | 2019 | 4566 | 0.140 |
Why?
|
| Cardiac Electrophysiology | 1 | 2015 | 48 | 0.130 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2019 | 346 | 0.130 |
Why?
|
| Steam | 1 | 2015 | 31 | 0.130 |
Why?
|
| Diagnosis, Differential | 6 | 2020 | 12958 | 0.130 |
Why?
|
| Genetics, Population | 2 | 2018 | 933 | 0.130 |
Why?
|
| Necrosis | 1 | 2019 | 1643 | 0.130 |
Why?
|
| Logistic Models | 8 | 2017 | 13403 | 0.130 |
Why?
|
| Sleep Apnea, Central | 1 | 2016 | 84 | 0.130 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2019 | 577 | 0.130 |
Why?
|
| Vectorcardiography | 1 | 2014 | 43 | 0.130 |
Why?
|
| United States | 17 | 2021 | 69693 | 0.130 |
Why?
|
| Loligo | 1 | 2014 | 1 | 0.130 |
Why?
|
| Desmosomes | 1 | 2014 | 73 | 0.120 |
Why?
|
| Polymorphism, Genetic | 3 | 2018 | 4328 | 0.120 |
Why?
|
| Electroshock | 1 | 2014 | 122 | 0.120 |
Why?
|
| Geological Phenomena | 1 | 2014 | 11 | 0.120 |
Why?
|
| Water Movements | 1 | 2014 | 17 | 0.120 |
Why?
|
| Hemorrhage | 2 | 2023 | 3461 | 0.120 |
Why?
|
| Consensus | 2 | 2020 | 2935 | 0.120 |
Why?
|
| Osmolar Concentration | 1 | 2015 | 683 | 0.120 |
Why?
|
| Friction | 1 | 2013 | 59 | 0.120 |
Why?
|
| Prevalence | 7 | 2022 | 15194 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2006 | 2866 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2023 | 2714 | 0.110 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2014 | 153 | 0.110 |
Why?
|
| Retreatment | 1 | 2015 | 604 | 0.110 |
Why?
|
| Chi-Square Distribution | 4 | 2015 | 3510 | 0.110 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2023 | 1129 | 0.110 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2012 | 64 | 0.110 |
Why?
|
| Depression | 2 | 2003 | 7733 | 0.110 |
Why?
|
| Heparin | 1 | 2020 | 1636 | 0.110 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2013 | 124 | 0.110 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2015 | 271 | 0.110 |
Why?
|
| Heart Valve Diseases | 1 | 2020 | 1067 | 0.100 |
Why?
|
| Transposition of Great Vessels | 2 | 2013 | 585 | 0.100 |
Why?
|
| Biological Evolution | 1 | 2018 | 1074 | 0.100 |
Why?
|
| Insulin Resistance | 1 | 2006 | 3861 | 0.100 |
Why?
|
| Societies, Medical | 2 | 2020 | 3740 | 0.100 |
Why?
|
| Case-Control Studies | 8 | 2012 | 21719 | 0.100 |
Why?
|
| Mediastinal Diseases | 1 | 2012 | 89 | 0.100 |
Why?
|
| Phlebography | 1 | 2013 | 333 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2014 | 35342 | 0.100 |
Why?
|
| Comorbidity | 6 | 2017 | 10372 | 0.100 |
Why?
|
| Preoperative Care | 2 | 2018 | 2245 | 0.100 |
Why?
|
| Antidepressive Agents | 1 | 2003 | 2838 | 0.100 |
Why?
|
| Insulin | 1 | 2006 | 6575 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 9941 | 0.100 |
Why?
|
| Models, Cardiovascular | 1 | 2016 | 994 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 8621 | 0.090 |
Why?
|
| Surface Properties | 1 | 2013 | 1182 | 0.090 |
Why?
|
| Models, Animal | 1 | 2017 | 2170 | 0.090 |
Why?
|
| Death, Sudden | 1 | 2012 | 298 | 0.090 |
Why?
|
| Lymphatic Diseases | 1 | 2012 | 324 | 0.090 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 12344 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 4465 | 0.090 |
Why?
|
| Adiposity | 1 | 2020 | 1806 | 0.090 |
Why?
|
| Brugada Syndrome | 1 | 2011 | 97 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2023 | 1808 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2014 | 14720 | 0.090 |
Why?
|
| Spermatozoa | 1 | 2014 | 625 | 0.090 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 839 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2015 | 859 | 0.090 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 2013 | 0.090 |
Why?
|
| Motion | 1 | 2013 | 797 | 0.090 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2013 | 277 | 0.090 |
Why?
|
| Genetic Variation | 3 | 2018 | 6540 | 0.090 |
Why?
|
| Fontan Procedure | 1 | 2016 | 768 | 0.090 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2019 | 1415 | 0.090 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2016 | 964 | 0.090 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2017 | 1527 | 0.090 |
Why?
|
| Medical Records | 1 | 2015 | 1413 | 0.090 |
Why?
|
| Latin America | 2 | 2020 | 381 | 0.080 |
Why?
|
| Heart Valve Prosthesis | 1 | 2018 | 1486 | 0.080 |
Why?
|
| Asia | 2 | 2020 | 607 | 0.080 |
Why?
|
| Fluoroscopy | 1 | 2013 | 924 | 0.080 |
Why?
|
| Exanthema | 1 | 2013 | 488 | 0.080 |
Why?
|
| Radiopharmaceuticals | 2 | 2022 | 2658 | 0.080 |
Why?
|
| False Negative Reactions | 1 | 2009 | 587 | 0.080 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2013 | 578 | 0.080 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2011 | 503 | 0.080 |
Why?
|
| Smoking | 2 | 2002 | 8969 | 0.080 |
Why?
|
| Adipose Tissue | 1 | 2020 | 3278 | 0.080 |
Why?
|
| Young Adult | 11 | 2021 | 56350 | 0.080 |
Why?
|
| Hemodynamics | 1 | 2017 | 4197 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2016 | 18006 | 0.070 |
Why?
|
| Algorithms | 2 | 2006 | 13853 | 0.070 |
Why?
|
| Atlantic Ocean | 2 | 2018 | 27 | 0.070 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2003 | 1873 | 0.070 |
Why?
|
| Analysis of Variance | 2 | 2014 | 6365 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2011 | 1184 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2011 | 1159 | 0.070 |
Why?
|
| Clinical Competence | 3 | 2015 | 4681 | 0.070 |
Why?
|
| Radiography, Interventional | 1 | 2013 | 1095 | 0.070 |
Why?
|
| Sleep | 2 | 2023 | 4604 | 0.070 |
Why?
|
| Prognosis | 5 | 2019 | 29010 | 0.060 |
Why?
|
| Phenotype | 3 | 2018 | 16331 | 0.060 |
Why?
|
| Lisinopril | 1 | 2004 | 54 | 0.060 |
Why?
|
| Disease Progression | 2 | 2019 | 13256 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 6483 | 0.060 |
Why?
|
| Antihypertensive Agents | 2 | 2004 | 2043 | 0.060 |
Why?
|
| Morbidity | 2 | 2020 | 1767 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 1 | 2013 | 1483 | 0.060 |
Why?
|
| Sulfonylurea Compounds | 1 | 2006 | 204 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2016 | 1661 | 0.060 |
Why?
|
| Tetrahydroisoquinolines | 1 | 2004 | 91 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2011 | 1638 | 0.060 |
Why?
|
| Chest Pain | 1 | 2011 | 1113 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2010 | 1484 | 0.060 |
Why?
|
| Microsatellite Repeats | 2 | 2018 | 800 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2009 | 2970 | 0.060 |
Why?
|
| Genotype | 4 | 2021 | 12946 | 0.060 |
Why?
|
| Accidental Falls | 1 | 2011 | 1057 | 0.060 |
Why?
|
| Biopsy | 2 | 2015 | 6756 | 0.060 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 2283 | 0.060 |
Why?
|
| Aged, 80 and over | 11 | 2019 | 57683 | 0.060 |
Why?
|
| Thiazolidinediones | 1 | 2006 | 476 | 0.050 |
Why?
|
| Inpatients | 1 | 2014 | 2495 | 0.050 |
Why?
|
| Positron-Emission Tomography | 2 | 2022 | 6259 | 0.050 |
Why?
|
| Benzazepines | 1 | 2004 | 326 | 0.050 |
Why?
|
| Hospital Mortality | 3 | 2020 | 5310 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3130 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3236 | 0.050 |
Why?
|
| Patient Discharge | 1 | 2015 | 3300 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2017 | 3306 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 11695 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2003 | 1159 | 0.050 |
Why?
|
| Coronary Angiography | 1 | 2013 | 4567 | 0.050 |
Why?
|
| Pneumonectomy | 1 | 2008 | 1093 | 0.050 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2003 | 322 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 689 | 0.050 |
Why?
|
| Lysosomal-Associated Membrane Protein 2 | 1 | 2021 | 52 | 0.050 |
Why?
|
| DNA, Mitochondrial | 2 | 2018 | 814 | 0.050 |
Why?
|
| Chloroquine | 1 | 2022 | 280 | 0.050 |
Why?
|
| Polysomnography | 2 | 2017 | 1772 | 0.050 |
Why?
|
| Pandemics | 1 | 2020 | 8328 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2003 | 641 | 0.040 |
Why?
|
| ROC Curve | 2 | 2018 | 3528 | 0.040 |
Why?
|
| Models, Biological | 1 | 2016 | 9581 | 0.040 |
Why?
|
| Remote Sensing Technology | 1 | 2020 | 90 | 0.040 |
Why?
|
| Mortality | 2 | 2022 | 2857 | 0.040 |
Why?
|
| Lung | 1 | 2017 | 9826 | 0.040 |
Why?
|
| Proteins | 1 | 2014 | 6096 | 0.040 |
Why?
|
| Metformin | 1 | 2006 | 829 | 0.040 |
Why?
|
| Databases, Factual | 3 | 2020 | 7716 | 0.040 |
Why?
|
| Tomography | 1 | 2020 | 388 | 0.040 |
Why?
|
| Seizures | 1 | 2011 | 2851 | 0.040 |
Why?
|
| Angola | 1 | 2018 | 16 | 0.040 |
Why?
|
| Electronics | 1 | 2020 | 322 | 0.040 |
Why?
|
| Depressive Disorder | 1 | 2011 | 3748 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2004 | 923 | 0.040 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2017 | 25 | 0.040 |
Why?
|
| Sample Size | 1 | 2001 | 844 | 0.040 |
Why?
|
| Adolescent | 8 | 2021 | 85649 | 0.040 |
Why?
|
| Decision Making | 1 | 2011 | 3869 | 0.040 |
Why?
|
| India | 2 | 2015 | 2187 | 0.040 |
Why?
|
| Antithrombins | 1 | 2020 | 304 | 0.040 |
Why?
|
| Decision Trees | 1 | 2018 | 506 | 0.040 |
Why?
|
| Vascular Surgical Procedures | 1 | 2005 | 1473 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2002 | 2295 | 0.040 |
Why?
|
| Tricuspid Valve | 1 | 2019 | 400 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2006 | 6452 | 0.030 |
Why?
|
| Probability | 1 | 2002 | 2502 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2006 | 2924 | 0.030 |
Why?
|
| Germany | 1 | 2018 | 860 | 0.030 |
Why?
|
| Age Distribution | 1 | 2002 | 2900 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2017 | 256 | 0.030 |
Why?
|
| Italy | 1 | 2017 | 828 | 0.030 |
Why?
|
| DNA | 2 | 2021 | 7289 | 0.030 |
Why?
|
| Credentialing | 1 | 2015 | 126 | 0.030 |
Why?
|
| Pedigree | 2 | 2014 | 4646 | 0.030 |
Why?
|
| Health Planning Guidelines | 1 | 2015 | 163 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2019 | 676 | 0.030 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2016 | 151 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2012 | 1608 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2005 | 2145 | 0.030 |
Why?
|
| Reference Values | 1 | 2002 | 4982 | 0.030 |
Why?
|
| Hypertension | 2 | 2004 | 8455 | 0.030 |
Why?
|
| Feasibility Studies | 2 | 2015 | 5062 | 0.030 |
Why?
|
| Phylogeography | 1 | 2014 | 81 | 0.030 |
Why?
|
| Fragile X Syndrome | 1 | 1995 | 115 | 0.030 |
Why?
|
| Gene Flow | 1 | 2014 | 79 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2015 | 520 | 0.030 |
Why?
|
| Dyneins | 1 | 2014 | 123 | 0.030 |
Why?
|
| Sex Factors | 2 | 2018 | 10392 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 1995 | 462 | 0.030 |
Why?
|
| Europe | 1 | 2020 | 3339 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2014 | 1538 | 0.030 |
Why?
|
| Species Specificity | 2 | 2014 | 2479 | 0.030 |
Why?
|
| Independent Living | 1 | 2017 | 564 | 0.030 |
Why?
|
| Solvents | 1 | 2014 | 302 | 0.030 |
Why?
|
| South Africa | 1 | 2018 | 1728 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 2002 | 2281 | 0.030 |
Why?
|
| Hospitalization | 2 | 2012 | 10232 | 0.030 |
Why?
|
| Education | 1 | 2015 | 543 | 0.030 |
Why?
|
| Artifacts | 2 | 2014 | 1903 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 3769 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 4187 | 0.030 |
Why?
|
| Cardiovascular Diseases | 2 | 2016 | 15108 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2011 | 7645 | 0.030 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 19862 | 0.030 |
Why?
|
| Situs Inversus | 1 | 2011 | 64 | 0.020 |
Why?
|
| Haplotypes | 1 | 2018 | 2781 | 0.020 |
Why?
|
| North America | 1 | 2015 | 1249 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2016 | 1770 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2011 | 6454 | 0.020 |
Why?
|
| Stents | 1 | 2003 | 3276 | 0.020 |
Why?
|
| Mitral Valve | 1 | 2019 | 1484 | 0.020 |
Why?
|
| Risk | 1 | 2003 | 9679 | 0.020 |
Why?
|
| Injections | 1 | 2014 | 840 | 0.020 |
Why?
|
| Age Factors | 2 | 2018 | 18355 | 0.020 |
Why?
|
| Phylogeny | 1 | 2018 | 2797 | 0.020 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2013 | 269 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2003 | 3067 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2003 | 5019 | 0.020 |
Why?
|
| Penetrance | 1 | 2011 | 380 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2016 | 1440 | 0.020 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 865 | 0.020 |
Why?
|
| Exercise Test | 1 | 2017 | 2075 | 0.020 |
Why?
|
| Child | 4 | 2021 | 77478 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 15530 | 0.020 |
Why?
|
| Hospitals | 1 | 2002 | 3937 | 0.020 |
Why?
|
| Homozygote | 1 | 2012 | 1777 | 0.020 |
Why?
|
| Ligation | 1 | 2008 | 453 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2014 | 2110 | 0.020 |
Why?
|
| Age of Onset | 1 | 2014 | 3266 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2014 | 2633 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2022 | 4595 | 0.020 |
Why?
|
| New York | 1 | 2010 | 886 | 0.020 |
Why?
|
| Canada | 1 | 2012 | 2061 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 1066 | 0.020 |
Why?
|
| Rats | 1 | 2023 | 24265 | 0.020 |
Why?
|
| Family Health | 1 | 2011 | 1282 | 0.020 |
Why?
|
| Polytetrafluoroethylene | 1 | 2007 | 233 | 0.020 |
Why?
|
| Heterozygote | 1 | 2012 | 2790 | 0.020 |
Why?
|
| Fatigue | 1 | 2013 | 1526 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 1989 | 0.020 |
Why?
|
| Point Mutation | 1 | 2011 | 1624 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2018 | 10248 | 0.020 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2013 | 1009 | 0.020 |
Why?
|
| Self Report | 1 | 2016 | 3548 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 10943 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9185 | 0.020 |
Why?
|
| Syndrome | 1 | 2011 | 3248 | 0.020 |
Why?
|
| Patients | 1 | 2011 | 892 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2017 | 3439 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 6891 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2022 | 7153 | 0.010 |
Why?
|
| Proteome | 1 | 2014 | 1790 | 0.010 |
Why?
|
| Sensory Thresholds | 1 | 2005 | 394 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2017 | 12017 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2011 | 13814 | 0.010 |
Why?
|
| Qualitative Research | 1 | 2011 | 2680 | 0.010 |
Why?
|
| Metals | 1 | 2007 | 717 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2011 | 18112 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2014 | 13029 | 0.010 |
Why?
|
| Curriculum | 1 | 2015 | 3589 | 0.010 |
Why?
|
| Inflammation | 1 | 2022 | 10578 | 0.010 |
Why?
|
| Postoperative Period | 1 | 2006 | 1839 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2011 | 1436 | 0.010 |
Why?
|
| Length of Stay | 1 | 2014 | 6294 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 3507 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 815 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 1185 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2020 | 25575 | 0.010 |
Why?
|
| Skin | 1 | 2013 | 4353 | 0.010 |
Why?
|
| Coronary Restenosis | 1 | 2002 | 424 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2016 | 12695 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2011 | 3215 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 2615 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 3915 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 2 | 2005 | 7276 | 0.010 |
Why?
|
| Mutation | 1 | 2021 | 29717 | 0.010 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 1995 | 117 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 15494 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 24913 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2006 | 4029 | 0.010 |
Why?
|
| Xenopus Proteins | 1 | 1995 | 433 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1995 | 1202 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1995 | 2049 | 0.010 |
Why?
|
| Xenopus laevis | 1 | 1995 | 956 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1995 | 2335 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1995 | 2837 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 5979 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1995 | 4322 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1995 | 4742 | 0.000 |
Why?
|
| RNA-Binding Proteins | 1 | 1995 | 1899 | 0.000 |
Why?
|
| Base Sequence | 1 | 1995 | 12797 | 0.000 |
Why?
|
| Gene Expression | 1 | 1995 | 7790 | 0.000 |
Why?
|